HC Wainwright Reaffirms Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN)

HC Wainwright reaffirmed their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN) in a research report report published on Thursday, Benzinga reports. They currently have a $17.00 price objective on the biopharmaceutical company’s stock.

Palatin Technologies Trading Up 0.9 %

NYSEAMERICAN PTN opened at $1.10 on Thursday. The firm has a market cap of $21.51 million, a PE ratio of -0.53 and a beta of 0.99. Palatin Technologies has a 1-year low of $0.68 and a 1-year high of $5.65.

Palatin Technologies (NYSEAMERICAN:PTN) last posted its earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share for the quarter. As a group, analysts forecast that Palatin Technologies will post -2.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Palatin Technologies stock. XTX Topco Ltd acquired a new stake in shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned 0.08% of Palatin Technologies at the end of the most recent quarter. Institutional investors own 11.50% of the company’s stock.

About Palatin Technologies

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.